A citation-based method for searching scientific literature

Mingzhao Xing. Nat Rev Cancer 2013
Times Cited: 842







List of co-cited articles
588 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
29

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
517
16

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
894
15

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
791
14

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
593
13

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
533
13

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
10

BRAF mutation in thyroid cancer.
M Xing. Endocr Relat Cancer 2005
918
9

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
70
12

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
445
9

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
830
9

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
8

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
320
8

The changing incidence of thyroid cancer.
Cari M Kitahara, Julie A Sosa. Nat Rev Endocrinol 2016
410
8

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
67
11

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
8

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
564
8

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.
Zhi Liu, Peng Hou, Meiju Ji, Haixia Guan, Kimberly Studeman, Kirk Jensen, Vasily Vasko, Adel K El-Naggar, Mingzhao Xing. J Clin Endocrinol Metab 2008
282
7

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
7

Phase II trial of sorafenib in advanced thyroid cancer.
Vandana Gupta-Abramson, Andrea B Troxel, Anoma Nellore, Kanchan Puttaswamy, Maryann Redlinger, Kathy Ransone, Susan J Mandel, Keith T Flaherty, Laurie A Loevner, Peter J O'Dwyer,[...]. J Clin Oncol 2008
494
7


Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
231
7

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
824
7

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
155
7

Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
371
7


Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Lindsey M Kelly, Guillermo Barila, Pengyuan Liu, Viktoria N Evdokimova, Sumita Trivedi, Federica Panebianco, Manoj Gandhi, Sally E Carty, Steven P Hodak, Jianhua Luo,[...]. Proc Natl Acad Sci U S A 2014
163
6

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
892
6

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
160
6

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
C Durante, E Puxeddu, E Ferretti, R Morisi, S Moretti, R Bruno, F Barbi, N Avenia, A Scipioni, A Verrienti,[...]. J Clin Endocrinol Metab 2007
266
6

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
139
6

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
309
6

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
406
6

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
154
6

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
185
6

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
705
6

Progress in molecular-based management of differentiated thyroid cancer.
Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
343
6

Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma.
Zheming Lu, Yujie Zhang, Dongdong Feng, Jindong Sheng, Wenjun Yang, Baoguo Liu. Oncotarget 2017
28
17

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
Yuri E Nikiforov, Sally E Carty, Simon I Chiosea, Christopher Coyne, Umamaheswar Duvvuri, Robert L Ferris, William E Gooding, Shane O LeBeau, N Paul Ohori, Raja R Seethala,[...]. Thyroid 2015
235
5

Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
Marina N Nikiforova, Abigail I Wald, Somak Roy, Mary Beth Durso, Yuri E Nikiforov. J Clin Endocrinol Metab 2013
298
5

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
189
5


Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
376
5

Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Peng Hou, Dingxie Liu, Yuan Shan, Shuiying Hu, Kimberley Studeman, Stephen Condouris, Yangang Wang, Ariel Trink, Adel K El-Naggar, Giovanni Tallini,[...]. Clin Cancer Res 2007
282
5

Pathogenetic mechanisms in thyroid follicular-cell neoplasia.
Tetsuo Kondo, Shereen Ezzat, Sylvia L Asa. Nat Rev Cancer 2006
640
5

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura,[...]. Future Oncol 2019
63
7

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, Adelaïde Doussau, Christine Do Cao, Julien Asselineau, Patrice Rodien, Damien Pouessel, Patricia Nicolli-Sire, Marc Klein,[...]. Eur J Cancer 2017
58
8

Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Athanasios Bikas, Priya Kundra, Sameer Desale, Mihriye Mete, Kaitlyn O'Keefe, Brandon G Clark, Lynette Wray, Rahul Gandhi, Christina Barett, James S Jelinek,[...]. Eur J Endocrinol 2016
35
14

Thyroid cancer.
Tobias Carling, Robert Udelsman. Annu Rev Med 2014
169
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.